EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis

Joan Carles iD, Rafael A Medina-Lopez iD, Javier Puente iD, Álvaro Gómez-Ferrer iD, Javier Casas Nebra iD, María Isabel Sáez Medina iD, Maria J Ribal iD, Alfredo Rodríguez Antolín iD, José Luís Álvarez-Ossorio iD, José Francisco Suárez Novo iD, Cristina Moretones Agut, Shankar Srinivasan iD und 2 weitere

Future Oncology · 2023

DOI: 10.2217/fon-2022-1131 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Future Oncology, 2023. Verfasst von Joan Carles und 13 weiteren Autor:innen. Beteiligte Einrichtung: Vall d'Hebron Institute of Oncology, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bayer HealthCare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Darolutamide significantly prolonged metastasis-free survival (MFS) versus placebo in the Phase III ARAMIS study. We analyzed outcomes in Spanish participants in ARAMIS. Patients & methods: Patients with high-risk nonmetastatic castration-resistant prostate cancer were randomized 2:1 to darolutamide 600 mg twice daily or placebo, plus androgen-deprivation therapy. The primary end point was MFS. Descriptive statistics are reported for this post hoc analysis.

Results

In Spanish participants, darolutamide (n = 75) prolonged MFS versus placebo (n = 42): hazard ratio 0.345, 95% confidence interval 0.175-0.681. The incidence and type of treatment-emergent adverse events were comparable between treatment arms.

Conclusion

For Spanish participants in ARAMIS, efficacy outcomes favored darolutamide versus placebo, with a similar safety profile, consistent with the overall ARAMIS population. Clinical Trials Registration: NCT02200614 (ClinicalTrials.gov). Darolutamide is an oral treatment for a type of prostate cancer that has stopped responding to other treatments and is at risk of spreading to other parts of the body (termed “nonmetastatic castration-resistant prostate cancer” or “nmCRPC”). In the international ARAMIS study, patients treated with darolutamide lived longer without their cancer spreading than patients who were given placebo (sugar) pills. We wanted to know whether Spanish patients in ARAMIS had similar characteristics and treatment outcomes to other patients in the study. We found that the 75 Spanish patients who were treated with darolutamide had a significantly lower risk of their cancer spreading than the 42 Spanish patients who received placebo. The two groups of Spanish patients had similar side effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantMaleHumansAndrogen Receptor AntagonistsAndrogen AntagonistsPyrazoles

Stichwörter der Autor:innen

PSA progressionSpainSpanishandrogen receptor inhibitorcastration-resistant prostate cancerdarolutamidemetastasis-free survivalnonmetastaticprostate-specific antigen

Substanzen

Androgen Receptor AntagonistsdarolutamideAndrogen AntagonistsPyrazoles

Autor:innen und Institutionen

  • Vall d'Hebron Institute of Oncology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Urology Department, Vírgen del Rocío University Hospital, Seville, Spain.
  • Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain.
  • Instituto Valenciano de Oncologia, Valencia, Spain.
  • Hospital Universitario Lucus Augusti, Lugo, Spain.
  • UGCI of Medical Oncology, Hospitales Regional & Universitario Virgen de la Victoria, IBIMA, UMA, Malaga, Spain.

ORCID-Profile: Joan Carles, Rafael A Medina-Lopez, Javier Puente, Álvaro Gómez-Ferrer, Javier Casas Nebra, María Isabel Sáez Medina, Maria J Ribal, Alfredo Rodríguez Antolín, José Luís Álvarez-Ossorio, José Francisco Suárez Novo, Shankar Srinivasan, Karim Fizazi

Förderung

  • Bayer HealthCare

Zitieren

APA

Carles, J., Medina-Lopez, R. A., Puente, J., Gómez-Ferrer, Á., Nebra, J. C., Sáez Medina, M. I., Ribal, M. J., Antolín, A. R., Álvarez-Ossorio, J. L., Suárez Novo, J. F., Agut, C. M., Srinivasan, S., Ortiz, J., & Fizazi, K. (2023). Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis. Future Oncology. https://doi.org/10.2217/fon-2022-1131

Vancouver

Carles J, Medina-Lopez RA, Puente J, Gómez-Ferrer Á, Nebra JC, Sáez Medina MI, et al. Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis. Future Oncology. 2023. doi:10.2217/fon-2022-1131

BibTeX
@article{Carles2023,
  author = {Carles, Joan and Medina-Lopez, Rafael A and Puente, Javier and Gómez-Ferrer, Álvaro and Nebra, Javier Casas and Sáez Medina, María Isabel and Ribal, Maria J and Antolín, Alfredo Rodríguez and Álvarez-Ossorio, José Luís and Suárez Novo, José Francisco and Agut, Cristina Moretones and Srinivasan, Shankar and Ortiz, Jorge and Fizazi, Karim},
  title = {Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis},
  journal = {Future Oncology},
  year = {2023},
  doi = {10.2217/fon-2022-1131}
}
Kostenlos starten →